#BEGIN_DRUGCARD DB00303

# AHFS_Codes:
08:12.07.08

# ATC_Codes:
J01DH03

# Absorption:
Ertapenem is almost completely absorbed following intramuscular administration. The bioavailability of a 1 g intramuscular dose approximated 92% in 26 healthy subjects [77% male; median (range) age, 29 (22â€“41) years]. Plasma concentrations of total ertapenem were similar whether given intramuscularly or intravenously.

# Biotransformation:
The major metabolite is the inactive ring-opened derivative formed by hydrolysis of the &beta;-lactam ring. Ertapenem did not inhibit metabolism mediated by cytochrome P450 (CYP) isoforms 1A2, 2C9, 2C19, 2D6, 2E1, or 3A4 when evaluated by in vitro studies in human liver microsomes. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected [PMID: 15150180]

# Brand_Mixtures:
Not Available

# Brand_Names:
Invanz

# CAS_Registry_Number:
153832-46-3

# ChEBI_ID:
404903

# Chemical_Formula:
C22H25N3O7S

# Chemical_IUPAC_Name:
(4R,5S,6S)-3-{[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2247437

# Description:
Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz&reg;. It is structurally very similar to meropenem in that it possess a 1-beta-methyl group. [Wikipedia]

# Dosage_Forms:
Powder, for solution	Intravenous

# Drug_Category:
Anti-Bacterial Agents
Antibacterial Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
15150180	Nix DE, Majumdar AK, DiNubile MJ: Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii23-8.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Soluble as sodium salt

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ertapenem

# HET_ID:
Not Available

# Half_Life:
The mean plasma half-life is approximately 4 hours.

# InChI_Identifier:
InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1

# InChI_Key:
InChIKey=JUZNIMUFDBIJCM-ANEDZVCMSA-N

# Indication:
For the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms: (1) complicated intra-abdominal infections due to <i>Escherichia coli</i>, <i>Clostridium clostridioforme</i>, <i>Eubacterium lentum</i>, <i>Peptostreptococcus</i> species, <i>Bacteroides fragilis</i>, <i>Bacteroides distasonis</i>, <i>Bacteroides ovatus</i>, <i>Bacteroides thetaiotaomicron</i>, or <i>Bacteroides uniformis</i>, (2) complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to <i>Staphylococcus aureus</i> (methicillin susceptible isolates only), <i>Streptococcus agalactiae</i>, <i>Streptococcus pyogenes</i>, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Proteus mirabilis</i>, <i>Bacteroides fragilis</i>, <i>Peptostreptococcus</i> species, <i>Porphyromonas asaccharolytica</i>, or <i>Prevotella bivia</i>, (3) community acquired pneumonia due to <i>Streptococcus pneumoniae</i> (penicillin susceptible isolates only) including cases with concurrent bacteremia, <i>Haemophilus influenzae</i> (beta-lactamase negative isolates only), or <i>Moraxella catarrhalis</i>, (4) complicated urinary tract infections including pyelonephritis due to <i>Escherichia coli</i>, including cases with concurrent bacteremia, or <i>Klebsiella pneumoniae</i>, (5) acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections due to <i>Streptococcus agalactiae</i>, <i>Escherichia coli</i>, <i>Bacteroides fragilis</i>, <i>Porphyromonas asaccharolytica</i>, <i>Peptostreptococcus</i> species, or <i>Prevotella bivia</i>.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D07908

# LIMS_Drug_ID:
303

# Mechanism_Of_Action:
The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In <i>Escherichia coli</i>, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Ertapenem is hydrolyzed by metallo-beta-lactamases.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
475.515

# Molecular_Weight_Mono:
475.141320859

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164777032

# Pharmacology:
Ertapenem has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria.

# Predicted_LogP_Hydrophobicity:
-0.2

# Predicted_LogS:
-3.2

# Predicted_Water_Solubility:
2.86e-01 g/l

# Primary_Accession_No:
DB00303

# Protein_Binding:
Ertapenem is highly bound to human plasma proteins, primarily albumin, in a concentration-dependent manner. The protein binding of ertapenem decreases as plasma concentrations increase. At a plasma concentration of &lt;100 &micro;g/mL, approximately 95% of ertapenem is protein bound. Protein binding of ertapenem decreases to approximately 85% at an approximate plasma concentration of 300 &micro;g/mL.

# PubChem_Compound_ID:
150610

# PubChem_Substance_ID:
46506508

# RxList_Link:
http://www.rxlist.com/cgi/generic3/invanz.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00952

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:14 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Ertapenem

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Bacterial cell inner membrane

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10223931	Kohler J, Dorso KL, Young K, Hammond GG, Rosen H, Kropp H, Silver LL: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother. 1999 May;43(5):1170-6.
11772242	Odenholt I: Ertapenem: a new carbapenem. Expert Opin Investig Drugs. 2001 Jun;10(6):1157-66.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L42023

# Drug_Target_1_GenBank_ID_Protein:
1572976

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
mrdA

# Drug_Target_1_Gene_Sequence:
>1956 bp
TTATCTTCCATTTATTTGTTCGCTCTCTTGTGACAAATCTTTTTTTTGCTGAATAGGTAC
ATTATATTTTTCAACTTGTGGTAAACGCTGATTTAAATAGTAATCCATCACTTTACGTGC
TAAGGGTGCGGCATTACTTGAACCACCACCTGCATTTTCTAAAATCACTGTTACAACTAA
TTTAGGATTATCATAAGGGGCGTAAGCGGTAAACCAAGCGTGATCATGCAATTCTTTTTT
TAAGCCTGCCGTATTATATTTTTCATTTTCCTTTAAACTAAACACTTGTGCAGTGCCAGA
TTTCCCTGCAACACGATAATTTGCATCTGCAAAGGCTTTTCGCCCAGTTCCATTTGCAGC
ATTAACAACATTGTACATACCGCGTTTCGCTGCCTCCCAAGCTGCCACTTTAGGTGTATT
AATATCAGGATAAAGTAACGGATCTTCATAAGGCTCTAATACTGCACCTTCAATTGCTTT
CATCAAATGCGGTGTATTTACTTTGCCATTATTGACCAATATTGTCGTCGCTTTTGCTAC
TTGTAGTGGTGTTGCCGTCCAATAACCTTGACCAATCCCAACCGAAATCGTATCGCCTTG
CACCCAAGGGCGTTTATAACGTTTTTGTTTCCATTCTCGAGTTGGTATATTGGCAGCCGT
TTCTTCTTGAATTTCAATCCCCGTTGGCATACCAAAACCAAAATCCTTCATCCAATTAGA
AAGGCGATCAATACCCATATTATAAGCCACTTGATAAAAATAAGTATCAGAGGATTCAGT
AATCGCTTTATTCAAATCCGTATCCCCGTGGCCTGTTTTTTTCCAATCACGAAAACGTTT
TGTGGAATTAGGTAATACCCAATATCCCGGATCAAAAATCGTTGTGTTTGGTGTAATCAC
ATTTTCAGTTTGTGCGGCTACTGCAATAAAAGGTTTGACTGTCGAAGCGGGCGGATACGC
ACCTTGTGTCGCACGACTATAAAGTGGACGAGCAAGATCATTTAATAAACGTTTATAATC
TTCGGAGGAAATACCATCAACAAATAAATTATTATCATAACTTGGTGTAGATACCATCGC
TAATACACTACTATCTTTCGGATCAAGCACAACTACAGCACCTTTTAGTCCCGATAAAAG
TTCAGTAATATAACGCTGTAATGCCAAATCAATGGTTAAATGAATACTTTTTCCCGCCAC
AGCAGGTCGGCTACGCAAAGTGCGGATTACTTTGCCGCGATTATTAATTTCTACTTCTTC
AAAACCCGTGGTACCTTGCAGTATATCCTCGTAATAACGTTCAATACCCAATTTTCCAAT
ATCGTTCGTTCCCGCATAATTCGCGAATTTATCCTCTCGTTTCAAACGTTCTACATCTTT
ATCATTCATTTTACCTACATAGCCCAAAATATGCGCCATTGTTTCGCCATATAAATAATG
GCGTTTGAAATAAGGACGTACCTCTAAGCTCGGGTATTGGTAGCCATTTACCGCAAAGCG
TGAAATTTGTTCTTCTGTTAAATTCGGCTTTAATAAAATCGGTGTATAACGCGTTCCGCG
GCGACGTTCCTTTTTAAAATTTTCAATATCGTTATCCGTCAATCCCACAATATAGCGTAA
TTCATCTAAAGTGCGGTCTAAATTTTCAGTTTTTTCTGGCACAATGTATAAACCAAAAAA
AGTAAGATTTTCGGCTAATAATTTGCCGTAACGATCATAGATTAAGCCACGTGTTGGCGG
TAAAGGTAATAATTTAATTCGGTTACCATTAGAACGCGTTTGGTAAGTATCGAAATTAAC
AATCTGTAGCTGATAAATATTGGTGAATAACACGCCTGTTAAGAGCAGAATCCCCAAAAA
AGCCACTAACGTTCGGCGTGCAAAAAGGTTACGCTCCGCTTTTTTATCGCGGAACGGTTC
GTGCGTTGGTGTATTGAAGAATTTTTTTAAATTCAT

# Drug_Target_1_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_1_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
115

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
73814

# Drug_Target_1_Name:
Penicillin-binding protein 2

# Drug_Target_1_Number_of_Residues:
651

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding protein 2
MNLKKFFNTPTHEPFRDKKAERNLFARRTLVAFLGILLLTGVLFTNIYQLQIVNFDTYQT
RSNGNRIKLLPLPPTRGLIYDRYGKLLAENLTFFGLYIVPEKTENLDRTLDELRYIVGLT
DNDIENFKKERRRGTRYTPILLKPNLTEEQISRFAVNGYQYPSLEVRPYFKRHYLYGETM
AHILGYVGKMNDKDVERLKREDKFANYAGTNDIGKLGIERYYEDILQGTTGFEEVEINNR
GKVIRTLRSRPAVAGKSIHLTIDLALQRYITELLSGLKGAVVVLDPKDSSVLAMVSTPSY
DNNLFVDGISSEDYKRLLNDLARPLYSRATQGAYPPASTVKPFIAVAAQTENVITPNTTI
FDPGYWVLPNSTKRFRDWKKTGHGDTDLNKAITESSDTYFYQVAYNMGIDRLSNWMKDFG
FGMPTGIEIQEETAANIPTREWKQKRYKRPWVQGDTISVGIGQGYWTATPLQVAKATTIL
VNNGKVNTPHLMKAIEGAVLEPYEDPLLYPDINTPKVAAWEAAKRGMYNVVNAANGTGRK
AFADANYRVAGKSGTAQVFSLKENEKYNTAGLKKELHDHAWFTAYAPYDNPKLVVTVILE
NAGGGSSNAAPLARKVMDYYLNQRLPQVEKYNVPIQQKKDLSQESEQINGR

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. Its synthesize cross- linked peptidoglycan from the lipid intermediates

# Drug_Target_1_SwissProt_ID:
P44469

# Drug_Target_1_SwissProt_Name:
PBP2_HAEIN

# Drug_Target_1_Synonyms:
PBP-2

# Drug_Target_1_Theoretical_pI:
9.66

# Drug_Target_1_Transmembrane_Regions:
30-52

# Drug_Target_2_Cellular_Location:
Cell inner membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10223931	Kohler J, Dorso KL, Young K, Hammond GG, Rosen H, Kropp H, Silver LL: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother. 1999 May;43(5):1170-6.

# Drug_Target_2_Essentiality:
Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
X04516

# Drug_Target_2_GenBank_ID_Protein:
42314

# Drug_Target_2_GeneCard_ID:
mrdA

# Drug_Target_2_Gene_Name:
mrdA

# Drug_Target_2_Gene_Sequence:
>210 bp
ATGATCATCTGTACGGGTACGTCCAGCCGTCATGTTATGTCCATTGCTGACCACGTTGTG
CAGGAGTCTCGCGCAGCGGGCCTGTTACCGCTCGGCGTAGAAGGTGAAAACAGCGCCGAC
TGGATTGTCGTGGATTTGGGCGATGTGATTGTCCATGTCATGCAGGAAGAGAGCCGTCGC
CTGTATGAACTGGAAAAACTCTGGAGTTAA

# Drug_Target_2_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_2_General_References:
16738553	Hayashi K, Morooka N, Yamamoto Y, Fujita K, Isono K, Choi S, Ohtsubo E, Baba T, Wanner BL, Mori H, Horiuchi T: Highly accurate genome sequences of Escherichia coli K-12 strains MG1655 and W3110. Mol Syst Biol. 2006;2:2006.0007. Epub 2006 Feb 21.
2644207	Matsuzawa H, Asoh S, Kunai K, Muraiso K, Takasuga A, Ohta T: Nucleotide sequence of the rodA gene, responsible for the rod shape of Escherichia coli: rodA and the pbpA gene, encoding penicillin-binding protein 2, constitute the rodA operon. J Bacteriol. 1989 Jan;171(1):558-60.
3533535	Asoh S, Matsuzawa H, Ishino F, Strominger JL, Matsuhashi M, Ohta T: Nucleotide sequence of the pbpA gene and characteristics of the deduced amino acid sequence of penicillin-binding protein 2 of Escherichia coli K12. Eur J Biochem. 1986 Oct 15;160(2):231-8.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-62.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6069

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
70856.1

# Drug_Target_2_Name:
Penicillin-binding protein 2

# Drug_Target_2_Number_of_Residues:
633

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer

# Drug_Target_2_Protein_Sequence:
>Penicillin-binding protein 2
MKLQNSFRDYTAESALFVRRALVAFLGILLLTGVLIANLYNLQIVRFTDYQTRSNENRIK
LVPIAPSRGIIYDRNGIPLALNRTIYQIEMMPEKVDNVQQTLDALRSVVDLTDDDIAAFR
KERARSHRFTSIPVKTNLTEVQVARFAVNQYRFPGVEVKGYKRRYYPYGSALTHVIGYVS
KINDKDVERLNNDGKLANYAATHDIGKLGIERYYEDVLHGQTGYEEVEVNNRGRVIRQLK
EVPPQAGHDIYLTLDLKLQQYIETLLAGSRAAVVVTDPRTGGVLALVSTPSYDPNLFVDG
ISSKDYSALLNDPNTPLVNRATQGVYPPASTVKPYVAVSALSAGVITRNTTLFDPGWWQL
PGSEKRYRDWKKWGHGRLNVTRSLEESADTFFYQVAYDMGIDRLSEWMGKFGYGHYTGID
LAEERSGNMPTREWKQKRFKKPWYQGDTIPVGIGQGYWTATPIQMSKALMILINDGIVKV
PHLLMSTAEDGKQVPWVQPHEPPVGDIHSGYWELAKDGMYGVANRPNGTAHKYFASAPYK
IAAKSGTAQVFGLKANETYNAHKIAERLRDHKLMTAFAPYNNPQVAVAMILENGGAGPAV
GTLMRQILDHIMLGDNNTDLPAENPAVAAAEDH

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Cell wall formation; PBP-2 is responsible for the determination of the rod shape of the cell. Its synthesize cross- linked peptidoglycan from the lipid intermediates

# Drug_Target_2_SwissProt_ID:
P0AD65

# Drug_Target_2_SwissProt_Name:
PBP2_ECOLI

# Drug_Target_2_Synonyms:
PBP-2

# Drug_Target_2_Theoretical_pI:
9.16

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Bacterial cell inner membrane (Potential)

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
10223931	Kohler J, Dorso KL, Young K, Hammond GG, Rosen H, Kropp H, Silver LL: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother. 1999 May;43(5):1170-6.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
L42023

# Drug_Target_3_GenBank_ID_Protein:
1574687

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
ftsI

# Drug_Target_3_Gene_Sequence:
>1833 bp
ATGGTGAAATTTAATTCCTCGCGTAAATCAGGTAAGTCAAAAAAAACAATTAGAAAATTG
ACCGCACCTGAAACTGTAAAGCAAAACAAGCCTCAAAAGGTGTTTGAAAAATGCTTTATG
CGTGGACGTTATATGCTTTCTACGGTTCTTATTTTACTTGGCCTGTGTGCTTTAGTCGCA
CGAGCAGCTTATGTTCAATCTATTAATGCCGATACGTTATCGAATGAAGCGGATAAGCGT
TCTTTGCGTAAAGATGAAGTATTATCGGTGCGTGGTTCTATTTTAGATCGTAATGGTCAG
CTTTTATCTGTAAGCGTGCCGATGAGCGCGATTGTGGCAGATCCAAAAACGATGTTGAAG
GAAAATTCGCTTGCGGATAAAGAACGAATTGCAGCTTTAGCCGAAGAATTAGGTATGACT
GAAAATGATTTAGTGAAAAAAATTGAGAAAAATTCTAAATCTGGTTATTTGTATTTAGCA
CGTCAAGTTGAATTAAGTAAAGCTAACTATATTCGTAGATTAAAAATTAAGGGTATTATT
TTAGAAACAGAGCATCGCCGTTTTTATCCTCGTGTAGAAGAAGCTGCACACGTGGTGGGT
TATACGGATATTGATGGAAATGGTATTGAAGGCATTGAGAAAAGTTTTAATTCCCTGCTT
GTTGGTAAAGACGGTTCACGTACTGTTCGTAAAGATAAACGTGGGAATATTGTTGCACAT
ATCTCCGATGAGAAAAAATATGATGCACAAGATGTTACCTTAAGTATCGATGAAAAATTG
CAATCTATGGTGTATCGTGAGATTAAAAAGGCGGTGTCTGAGAATAATGCTGAGTCTGGT
ACTGCGGTGTTAGTTGATGTTCGAACAGGGGAAGTGTTAGCTATGGCGACTGCGCCCTCT
TATAATCCAAACAACCGTGTCGGCGTGAAATCAGAGTTAATGCGTAACCGTGCAATTACC
GATACTTTTGAGCCAGGTTCTACGGTAAAACCTTTCGTTGTTTTAACCGCACTTCAACGA
GGTGTAGTTAAACGAGATGAAATTATTGATACTACGTCCTTTAAATTAAGCGGTAAAGAA
ATTGTGGACGTTGCACCACGTGCTCAGCAAACTTTAGACGAGATTTTAATGAACTCTAGT
AACCGTGGTGTAAGTCGTCTTGCATTACGTATGCCACCTAGTGCATTAATGGAAACTTAT
CAAAATGCAGGTTTAAGTAAACCGACAGATTTAGGCTTGATCGGAGAGCAAGTTGGGATT
TTGAATGCAAATCGTAAACGCTGGGCAGATATTGAGCGTGCAACAGTCGCTTATGGTTAT
GGTATTACTGCGACACCTTTACAAATTGCTCGTGCCTATGCAACCCTTGGTAGTTTCGGT
GTTTATCGTCCGCTTTCTATCACTAAAGTTGATCCGCCAGTTATTGGGAAACGGGTTTTC
TCTGAAAAAATAACTAAAGATATTGTGGGAATTTTAGAGAAAGTAGCAATTAAAAATAAA
CGCGCAATGGTGGAAGGCTACCGTGTCGGCGTAAAAACAGGTACGGCACGTAAGATTGAA
AATGGACATTATGTAAATAAGTATGTGGCATTTACTGCGGGTATTGCACCAATTAGTGAT
CCTCGTTATGCATTAGTGGTTTTGATCAATGATCCAAAAGCAGGAGAATATTATGGTGGT
GCGGTTTCTGCCCCTGTATTCTCTAACATTATGGGCTATGCGTTACGTGCAAATGCTATT
CCGCAAGATGCTGAAGCAGCTGAAAACACAACAACGAAAAGTGCAAAACGTATTGTTTAT
ATTGGCGAACACAAGAATCAAAAAGTGAATTAA

# Drug_Target_3_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_3_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
1

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
67167

# Drug_Target_3_Name:
Peptidoglycan synthetase ftsI

# Drug_Target_3_Number_of_Residues:
610

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer

# Drug_Target_3_Protein_Sequence:
>Peptidoglycan synthetase ftsI
MVKFNSSRKSGKSKKTIRKLTAPETVKQNKPQKVFEKCFMRGRYMLSTVLILLGLCALVA
RAAYVQSINADTLSNEADKRSLRKDEVLSVRGSILDRNGQLLSVSVPMSAIVADPKTMLK
ENSLADKERIAALAEELGMTENDLVKKIEKNSKSGYLYLARQVELSKANYIRRLKIKGII
LETEHRRFYPRVEEAAHVVGYTDIDGNGIEGIEKSFNSLLVGKDGSRTVRKDKRGNIVAH
ISDEKKYDAQDVTLSIDEKLQSMVYREIKKAVSENNAESGTAVLVDVRTGEVLAMATAPS
YNPNNRVGVKSELMRNRAITDTFEPGSTVKPFVVLTALQRGVVKRDEIIDTTSFKLSGKE
IVDVAPRAQQTLDEILMNSSNRGVSRLALRMPPSALMETYQNAGLSKPTDLGLIGEQVGI
LNANRKRWADIERATVAYGYGITATPLQIARAYATLGSFGVYRPLSITKVDPPVIGKRVF
SEKITKDIVGILEKVAIKNKRAMVEGYRVGVKTGTARKIENGHYVNKYVAFTAGIAPISD
PRYALVVLINDPKAGEYYGGAVSAPVFSNIMGYALRANAIPQDAEAAENTTTKSAKRIVY
IGEHKNQKVN

# Drug_Target_3_Reaction:
[GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)]n- diphosphoundecaprenol + GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)- diphosphoundecaprenol = [GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)]n+1- diphosphoundecaprenol + undecaprenyl diphosphate

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Cell wall formation. Essential for the formation of a septum of the murein sacculus. Synthesis of cross-linked peptidoglycan from the lipid intermediates

# Drug_Target_3_SwissProt_ID:
P45059

# Drug_Target_3_SwissProt_Name:
FTSI_HAEIN

# Drug_Target_3_Synonyms:
EC 2.4.1.129
PBP-3
Penicillin-binding protein 3
Peptidoglycan glycosyltransferase 3

# Drug_Target_3_Theoretical_pI:
10.24

# Drug_Target_3_Transmembrane_Regions:
43-65

# Drug_Target_4_Cellular_Location:
Cell inner membrane

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
10223931	Kohler J, Dorso KL, Young K, Hammond GG, Rosen H, Kropp H, Silver LL: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother. 1999 May;43(5):1170-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
K00137

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
ftsI

# Drug_Target_4_Gene_Sequence:
>1767 bp
ATGAAAGCAGCGGCGAAAACGCAGAAACCAAAACGTCAGGAAGAACATGCCAACTTTATC
AGTTGGCGTTTTGCGTTGTTATGCGGCTGTATTCTCCTGGCGCTGGCTTTTCTGCTCGGA
CGCGTAGCGTGGTTACAAGTTATCTCCCCGGATATGCTGGTGAAAGAGGGCGACATGCGT
TCTCTTCGCGTTCAGCAAGTTTCCACCTCCCGCGGCATGATTACTGACCGTTCTGGTCGC
CCGTTAGCGGTGAGCGTGCCGGTAAAAGCGATTTGGGCTGACCCGAAAGAAGTGCATGAC
GCTGGCGGTATCAGCGTCGGTGACCGCTGGAAGGCGCTGGCTAACGCGCTCAATATTCCG
CTGGATCAGCTTTCAGCCCGCATTAACGCCAACCCGAAAGGGCGCTTTATTTATCTGGCG
CGTCAGGTGAACCCTGACATGGCGGACTACATCAAAAAACTGAAACTGCCGGGGATTCAT
CTGCGTGAAGAGTCTCGCCGTTACTATCCGTCCGGCGAAGTGACTGCTCACCTCATCGGC
TTTACTAACGTCGATAGTCAAGGGATTGAGGGCGTTGAGAAGAGTTTCGATAAATGGCTT
ACCGGGCAGCCGGGTGAGCGCATTGTGCGTAAAGACCGCTATGGTCGCGTAATTGAAGAT
ATTTCTTCTACTGACAGCCAGGCAGCGCACAACCTGGCGCTGAGTATTGATGAACGCCTG
CAGGCGCTGGTTTATCGCGAACTGAACAACGCGGTGGCCTTTAACAAGGCTGAATCTGGT
AGCGCCGTGCTGGTGGATGTCAACACCGGTGAAGTGCTGGCGATGGCTAACAGCCCGTCA
TACAACCCTAACAATCTGAGCGGCACGCCGAAAGAGGCGATGCGTAACCGTACCATCACC
GACGTGTTTGAACCGGGCTCAACGGTTAAACCGATGGTGGTAATGACCGCGTTGCAACGT
GGCGTGGTGCGGGAAAACTCGGTACTCAATACCATTCCTTATCGAATTAACGGCCACGAA
ATCAAAGACGTGGCACGCTACAGCGAATTAACCCTGACCGGGGTATTACAGAAGTCGAGT
AACGTCGGTGTTTCCAAGCTGGCGTTAGCGATGCCGTCCTCAGCGTTAGTAGATACTTAC
TCACGTTTTGGACTGGGAAAAGCGACCAATTTGGGGTTGGTCGGAGAACGCAGTGGCTTA
TATCCTCAAAAACAACGGTGGTCTGACATAGAGAGGGCCACCTTCTCTTTCGGCTACGGG
CTAATGGTAACACCATTACAGTTAGCGCGAGTCTACGCAACTATCGGCAGCTACGGCATT
TATCGCCCACTGTCGATTACCAAAGTTGACCCCCCGGTTCCCGGTGAACGTGTCTTCCCG
GAATCCATTGTCCGCACTGTGGTGCATATGATGGAAAGCGTGGCGCTACCAGGCGGCGGC
GGCGTGAAGGCGGCGATTAAAGGCTATCGTATCGCCATTAAAACCGGTACCGCGAAAAAG
GTCGGGCCGGACGGTCGCTACATCAATAAATATATTGCTTATACCGCAGGCGTTGCGCCT
GCGAGTCAGCCGCGCTTCGCGCTGGTTGTTGTTATCAACGATCCGCAGGCGGGTAAATAC
TACGGCGGCGCCGTTTCCGCGCCGGTCTTTGGTGCCATCATGGGCGGCGTATTGCGTACC
ATGAACATCGAGCCGGATGCGCTGACAACGGGCGATAAAAATGAATTTGTGATTAATCAA
GGCGAGGGGACAGGTGGCAGATCGTAA

# Drug_Target_4_General_Function:
Involved in penicillin binding

# Drug_Target_4_General_References:
1332942	Guzman LM, Barondess JJ, Beckwith J: FtsL, an essential cytoplasmic membrane protein involved in cell division in Escherichia coli. J Bacteriol. 1992 Dec;174(23):7716-28.
1447153	Ueki M, Wachi M, Jung HK, Ishino F, Matsuhashi M: Escherichia coli mraR gene involved in cell growth and division. J Bacteriol. 1992 Dec;174(23):7841-3.
1630901	Yura T, Mori H, Nagai H, Nagata T, Ishihama A, Fujita N, Isono K, Mizobuchi K, Nakata A: Systematic sequencing of the Escherichia coli genome: analysis of the 0-2.4 min region. Nucleic Acids Res. 1992 Jul 11;20(13):3305-8.
2198024	Michaud C, Parquet C, Flouret B, Blanot D, van Heijenoort J: Revised interpretation of the sequence containing the murE gene encoding the UDP-N-acetylmuramyl-tripeptide synthetase of Escherichia coli. Biochem J. 1990 Jul 1;269(1):277-8.
2681146	Nagasawa H, Sakagami Y, Suzuki A, Suzuki H, Hara H, Hirota Y: Determination of the cleavage site involved in C-terminal processing of penicillin-binding protein 3 of Escherichia coli. J Bacteriol. 1989 Nov;171(11):5890-3.
3049550	Taschner PE, Ypenburg N, Spratt BG, Woldringh CL: An amino acid substitution in penicillin-binding protein 3 creates pointed polar caps in Escherichia coli. J Bacteriol. 1988 Oct;170(10):4828-37.
3911028	Houba-Herin N, Hara H, Inouye M, Hirota Y: Binding of penicillin to thiol-penicillin-binding protein 3 of Escherichia coli: identification of its active site. Mol Gen Genet. 1985;201(3):499-504.
6350821	Nakamura M, Maruyama IN, Soma M, Kato J, Suzuki H, Horota Y: On the process of cellular division in Escherichia coli: nucleotide sequence of the gene for penicillin-binding protein 3. Mol Gen Genet. 1983;191(1):1-9.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
4155

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
63878

# Drug_Target_4_Name:
Peptidoglycan synthetase ftsI

# Drug_Target_4_Number_of_Residues:
588

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer

# Drug_Target_4_Protein_Sequence:
>Peptidoglycan synthetase ftsI
MKAAAKTQKPKRQEEHANFISWRFALLCGCILLALAFLLGRVAWLQVISPDMLVKEGDMR
SLRVQQVSTSRGMITDRSGRPLAVSVPVKAIWADPKEVHDAGGISVGDRWKALANALNIP
LDQLSARINANPKGRFIYLARQVNPDMADYIKKLKLPGIHLREESRRYYPSGEVTAHLIG
FTNVDSQGIEGVEKSFDKWLTGQPGERIVRKDRYGRVIEDISSTDSQAAHNLALSIDERL
QALVYRELNNAVAFNKAESGSAVLVDVNTGEVLAMANSPSYNPNNLSGTPKEAMRNRTIT
DVFEPGSTVKPMVVMTALQRGVVRENSVLNTIPYRINGHEIKDVARYSELTLTGVLQKSS
NVGVSKLALAMPSSALVDTYSRFGLGKATNLGLVGERSGLYPQKQRWSDIERATFSFGYG
LMVTPLQLARVYATIGSYGIYRPLSITKVDPPVPGERVFPESIVRTVVHMMESVALPGGG
GVKAAIKGYRIAIKTGTAKKVGPDGRYINKYIAYTAGVAPASQPRFALVVVINDPQAGKY
YGGAVSAPVFGAIMGGVLRTMNIEPDALTTGDKNEFVINQGEGTGGRS

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Cell wall formation. Essential for the formation of a septum of the murein sacculus. Synthesis of cross-linked peptidoglycan from the lipid intermediates

# Drug_Target_4_SwissProt_ID:
P0AD68

# Drug_Target_4_SwissProt_Name:
FTSI_ECOLI

# Drug_Target_4_Synonyms:
EC 2.4.1.129
PBP-3
Penicillin-binding protein 3
Peptidoglycan glycosyltransferase 3
Peptidoglycan synthetase ftsI precursor

# Drug_Target_4_Theoretical_pI:
10.10

# Drug_Target_4_Transmembrane_Regions:
19-39

# Drug_Target_5_Cellular_Location:
Periplasm (Potential)

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
10223931	Kohler J, Dorso KL, Young K, Hammond GG, Rosen H, Kropp H, Silver LL: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother. 1999 May;43(5):1170-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
X59460

# Drug_Target_5_GenBank_ID_Protein:
41216

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
dacB

# Drug_Target_5_Gene_Sequence:
>1434 bp
ATGCGATTTTCCAGATTTATCATCGGATTGACCAGCTGTATAGCGTTCAGTGTTCAGGCC
GCAAATGTTGATGAGTACATTACTCAACTCCCCGCTGGTGCCAACCTTGCCCTGATGGTG
CAAAAAGTCGGCGCGTCGGCCCCCGCTATTGATTACCACAGTCAGCAGATGGCGCTGCCT
GCCAGTACCCAGAAAGTGATTACTGCGCTGGCGGCGTTGATTCAACTCGGCCCCGATTTT
CGTTTTACCACGACGCTTGAAACCAAAGGCAATGTGGAAAACGGCGTACTTAAGGGTGAC
TTAGTGGCGCGATTTGGTGCCGATCCGACGTTAAAACGTCAGGATATTCGCAATATGGTC
GCGACTTTGAAAAAATCTGGCGTCAACCAAATCGATGGCAATGTGTTGATAGATACCTCC
ATTTTCGCCAGCCACGATAAAGCCCCCGGCTGGCCATGGAATGACATGACACAATGCTTT
AGCGCTCCGCCTGCCGCCGCCATAGTTGACCGCAACTGTTTCTCCGTCTCGCTCTACAGT
GCCCCAAAGCCTGGTGATATGGCTTTTATACGCGTGGCATCTTATTACCCCGTTACGATG
TTCAGCCAGGTACGCACCCTCCCCCGTGGTTCTGCCGAAGCGCAATACTGCGAACTGGAT
GTGGTGCCAGGCGACCTGAACCGCTTTACGCTGACGGGATGCCTGCCACAACGTTCTGAG
CCGCTCCCGTTGGCTTTTGCCGTGCAGGATGGAGCCAGCTATGCCGGTGCAATTCTGAAA
GATGAGTTAAAACAGGCGGGTATCACCTGGAGCGGAACACTGCTGCGCCAGACTCAGGTT
AACGAACCTGGAACGGTAGTTGCCAGTAAACAGTCGGCCCCGCTGCACGATCTGCTTAAG
ATTATGCTGAAAAAGTCGGACAACATGATCGCCGATACGGTTTTCCGCATGATAGGCCAT
GCGCGCTTCAATGTGCCTGGAACATGGCGGGCCGGGTCGGACGCCGTGCGTCAGATCCTG
CGCCAGCAAGCCGGTGTCGATATTGGAAACACCATTATTGCCGATGGTTCAGGGCTTTCG
CGGCATAACCTGATTGCCCCCGCCACCATGATGCAGGTGCTGCAATACATTGCCCAACAC
GACAATGAACTTAACTTTATCTCCATGCTGCCGCTGGCGGGCTATGACGGCTCTTTGCAG
TACCGTGCAGGTCTGCATCAGGCGGGCGTGGATGGAAAAGTCTCAGCGAAAACCGGTTCG
TTGCAGGGGGTATATAACCTGGCGGGATTCATTACCACAGCGAGCGGGCAACGAATGGCG
TTTGTGCAATATCTTTCTGGCTATGCAGTAGAACCTGCGGATCAGCGTAATCGCCGTATT
CCGTTAGTGCGTTTTGAAAGCCGTTTGTATAAAGATATTTATCAGAACAATTAG

# Drug_Target_5_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_5_General_References:
2040429	Mottl H, Terpstra P, Keck W: Penicillin-binding protein 4 of Escherichia coli shows a novel type of primary structure among penicillin-interacting proteins. FEMS Microbiol Lett. 1991 Mar 1;62(2-3):213-20.
2046551	Korat B, Mottl H, Keck W: Penicillin-binding protein 4 of Escherichia coli: molecular cloning of the dacB gene, controlled overexpression, and alterations in murein composition. Mol Microbiol. 1991 Mar;5(3):675-84.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
819

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
51799

# Drug_Target_5_Name:
Penicillin-binding protein 4

# Drug_Target_5_Number_of_Residues:
477

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF02113	Peptidase_S13

# Drug_Target_5_Protein_Sequence:
>Penicillin-binding protein 4 precursor
MRFSRFIIGLTSCIAFSVQAANVDEYITQLPAGANLALMVQKVGASAPAIDYHSQQMALP
ASTQKVITALAALIQLGPDFRFTTTLETKGNVENGVLKGDLVARFGADPTLKRQDIRNMV
ATLKKSGVNQIDGNVLIDTSIFASHDKAPGWPWNDMTQCFSAPPAAAIVDRNCFSVSLYS
APKPGDMAFIRVASYYPVTMFSQVRTLPRGSAEAQYCELDVVPGDLNRFTLTGCLPQRSE
PLPLAFAVQDGASYAGAILKDELKQAGITWSGTLLRQTQVNEPGTVVASKQSAPLHDLLK
IMLKKSDNMIADTVFRMIGHARFNVPGTWRAGSDAVRQILRQQAGVDIGNTIIADGSGLS
RHNLIAPATMMQVLQYIAQHDNELNFISMLPLAGYDGSLQYRAGLHQAGVDGKVSAKTGS
LQGVYNLAGFITTASGQRMAFVQYLSGYAVEPADQRNRRIPLVRFESRLYKDIYQNN

# Drug_Target_5_Reaction:
Preferential cleavage: (Ac)2-L-Lys-D-Ala!D-Ala. Also transpeptidation of peptidyl-alanyl moieties that are N-acyl substituents of D-alanine INHIBITOR Penicillin; beta-Lactam antibiotics

# Drug_Target_5_Signals:
1-20

# Drug_Target_5_Specific_Function:
Not involved in transpeptidation but exclusively catalyzes a DD-carboxypeptidase and DD-endopeptidase reaction

# Drug_Target_5_SwissProt_ID:
P24228

# Drug_Target_5_SwissProt_Name:
DACB_ECOLI

# Drug_Target_5_Synonyms:
D-alanyl-D-alanine-endopeptidase
DD- carboxypeptidase
DD-peptidase
EC 3.4.16.4
EC 3.4.99.-
PBP-4
Penicillin-binding protein 4 precursor

# Drug_Target_5_Theoretical_pI:
9.02

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Bacterial cell inner membrane
single-pass type II membrane protein

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
10223931	Kohler J, Dorso KL, Young K, Hammond GG, Rosen H, Kropp H, Silver LL: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother. 1999 May;43(5):1170-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
X02164

# Drug_Target_6_GenBank_ID_Protein:
581194

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
mrcA

# Drug_Target_6_Gene_Sequence:
>2553 bp
GTGAAGTTCGTAAAGTATTTTTTGATCCTTGCAGTCTGTTGCATTCTGCTGGGAGCAGGC
TCGATTTATGGCCTATACCGCTACATCGAGCCACAACTGCCGGATGTGGCGACATTAAAA
GATGTTCGCCTGCAAATTCCGATGCAGATTTACAGCGCCGATGGCGAGCTGATTGCTCAA
TACGGTGAGAAACGTCGTATTCCGGTTACGTTGGATCAAATCCCACCGGAGATGGTGAAA
GCCTTTATCGCGACAGAAGACAGCCGCTTCTACGAGCATCACGGCGTTGACCCGGTGGGG
ATCTTCCGTGCAGCAAGCGTGGCGCTGTTCTCCGGTCACGCGTCACAAGGGGCAAGTACC
ATTACCCAGCAGCTGGCGAGAAACTTCTTCCTCAGTCCAGAACGCACGCTGATGCGTAAG
ATTAAGGAAGTCTTCCTCGCGATTCGCATTGAACAGCTGCTGACGAAAGACGAGATCCTC
GAGCTTTATCTGAACAAGATTTACCTTGGTTACCGCGCCTATGGTGTCGGTGCTGCGGCA
CAAGTCTATTTCGGAAAAACGGTCGACCAACTGACGCTGAACGAAATGGCGGTGATAGCC
GGGCTGCCGAAAGCGCCTTCCACCTTCAACCCGCTCTACTCGATGGATCGTGCCGTCGCG
CGGCGTAACGTCGTGCTGTCGCGGATGCTGGATGAAGGGTATATCACCCAACAACAGTTC
GATCAGACACGCACTGAGGCGATTAACGCTAACTATCACGCGCCGGAGATTGCTTTCTCT
GCGCCGTACCTGAGCGAAATGGTGCGCCAGGAGATGTATAACCGTTATGGCGAAAGTGCC
TATGAAGACGGTTATCGCATTTACACCACCATCACCCGCAAAGTGCAGCAGGCCGCGCAG
CAGGCGGTACGTAATAACGTGCTGGACTACGACATGCGCCACGGCTATCGCGGCCCGGCA
AATGTGCTGTGGAAAGTGGGCGAGTCGGCGTGGGATAACAACAAGATTACCGATACGCTG
AAGGCGCTGCCAACCTATGGTCCGCTGCTGCCTGCCGCAGTCACCAGCGCCAATCCTCAG
CAAGCGACGGCGATGCTGGCGGACGGGTCGACCGTCGCATTGAGTATGGAAGGCGTTCGC
TGGGCGCGTCCTTACCGTTCGGATACTCAGCAAGGACCGACGCCGCGTAAAGTGACCGAT
GTTCTGCAAACGGGTCAGCAAATCTGGGTTCGTCAGGTTGGCGATGCATGGTGGCTGGCA
CAAGTGCCGGAAGTGAACTCGGCGCTGGTGTCGATCAATCCGCAAAACGGTGCCGTTATG
GCGCTGGTCGGTGGCTTTGATTTCAATCAGAGCAAGTTTAACCGCGCCACCCAGGCACTG
CGTCAGGTGGGTTCCAACATCAAACCGTTCCTCTACACCGCGGCGATGGATAAAGGTCTG
ACGCTGGCAAGTATGTTGAACGATGTGCCAATTTCTCGCTGGGATGCAAGTGCCGGTTCT
GACTGGCAGCCGAAGAACTCACCACCGCAGTATGCTGGTCCAATTCGCTTACGTCAGGGG
CTGGGTCAGTCGAAAAACGTGGTGATGGTACGCGCAATGCGGGCGATGGGCGTCGACTAC
GCTGCAGAATATCTGCAACGCTTCGGCTTCCCGGCACAAAACATTGTCCACACCGAATCG
CTGGCGCTGGGTTCAGCGTCCTTCACCCCAATGCAGGTGGCGCGCGGCTACGCGGTCATG
GCGAACGGCGGCTTCCTGGTGGACCCGTGGTTTATCAGCAAAATTGAAAACGATCAGGGC
GGCGTGATTTTCGAAGCGAAACCGAAAGTAGCCTGCCCGGAATGCGATATTCCGGTGATT
TACGGTGATACGCAGAAATCGAACGTGCTGGAAAATAACGATGTTGAAGATGTCGCTATC
TCCCGCGAGCAGCAGAATGTTTCTGTACCAATGCCGCAGCTGGAGCAGGCAAATCAGGCG
TTAGTGGCGAAGACTGGCGCGCAGGAGTACGCACCGCACGTCATCAACACTCCGCTGGCA
TTCCTGATTAAGAGTGCTTTGAACACCAATATCTTTGGTGAGCCAGGCTGGCAGGGTACT
GGCTGGCGTGCAGGTCGTGATTTGCAGCGTCGCGATATCGGCGGGAAAACCGGGACCACT
AACAGTTCGAAAGATGCGTGGTTCTCGGGTTACGGTCCGGGCGTTGTGACCTCGGTCTGG
ATTGGCTTTGATGATCACCGTCGTAATCTCGGTCATACAACGGCTTCCGGAGCGATTAAA
GATCAGATCTCAGGTTACGAAGGCGGTGCCAAGAGTGCCCAGCCTGCATGGGACGCTTAT
ATGAAAGCCGTTCTTGAAGGTGTGCCGGAGCAGCCGCTGACGCCGCCACCGGGTATTGTG
ACGGTGAATATCGATCGCAGCACCGGGCAGTTAGCTAATGGTGGCAACAGCCGCGAAGAG
TATTTCATCGAAGGTACGCAGCCGACACAACAGGCAGTGCACGAGGTGGGAACGACCATT
ATCGATAATGGCGAGGCACAGGAATTGTTCTGA

# Drug_Target_6_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_6_General_References:
3882429	Broome-Smith JK, Edelman A, Yousif S, Spratt BG: The nucleotide sequences of the ponA and ponB genes encoding penicillin-binding protein 1A and 1B of Escherichia coli K12. Eur J Biochem. 1985 Mar 1;147(2):437-46.
3920658	Keck W, Glauner B, Schwarz U, Broome-Smith JK, Spratt BG: Sequences of the active-site peptides of three of the high-Mr penicillin-binding proteins of Escherichia coli K-12. Proc Natl Acad Sci U S A. 1985 Apr;82(7):1999-2003.
7006606	Ishino F, Mitsui K, Tamaki S, Matsuhashi M: Dual enzyme activities of cell wall peptidoglycan synthesis, peptidoglycan transglycosylase and penicillin-sensitive transpeptidase, in purified preparations of Escherichia coli penicillin-binding protein 1A. Biochem Biophys Res Commun. 1980 Nov 17;97(1):287-93.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9841666	Goffin C, Ghuysen JM: Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol Mol Biol Rev. 1998 Dec;62(4):1079-93.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
645

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
93637

# Drug_Target_6_Name:
Penicillin-binding protein 1A

# Drug_Target_6_Number_of_Residues:
850

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00905	Transpeptidase
PF00912	Transgly

# Drug_Target_6_Protein_Sequence:
>Penicillin-binding protein 1A
MKFVKYFLILAVCCILLGAGSIYGLYRYIEPQLPDVATLKDVRLQIPMQIYSADGELIAQ
YGEKRRIPVTLDQIPPEMVKAFIATEDSRFYEHHGVDPVGIFRAASVALFSGHASQGAST
ITQQLARNFFLSPERTLMRKIKEVFLAIRIEQLLTKDEILELYLNKIYLGYRAYGVGAAA
QVYFGKTVDQLTLNEMAVIAGLPKAPSTFNPLYSMDRAVARRNVVLSRMLDEGYITQQQF
DQTRTEAINANYHAPEIAFSAPYLSEMVRQEMYNRYGESAYEDGYRIYTTITRKVQQAAQ
QAVRNNVLDYDMRHGYRGPANVLWKVGESAWDNNKITDTLKALPTYGPLLPAAVTSANPQ
QATAMLADGSTVALSMEGVRWARPYRSDTQQGPTPRKVTDVLQTGQQIWVRQVGDAWWLA
QVPEVNSALVSINPQNGAVMALVGGFDFNQSKFNRATQALRQVGSNIKPFLYTAAMDKGL
TLASMLNDVPISRWDASAGSDWQPKNSPPQYAGPIRLRQGLGQSKNVVMVRAMRAMGVDY
AAEYLQRFGFPAQNIVHTESLALGSASFTPMQVARGYAVMANGGFLVDPWFISKIENDQG
GVIFEAKPKVACPECDIPVIYGDTQKSNVLENNDVEDVAISREQQNVSVPMPQLEQANQA
LVAKTGAQEYAPHVINTPLAFLIKSALNTNIFGEPGWQGTGWRAGRDLQRRDIGGKTGTT
NSSKDAWFSGYGPGVVTSVWIGFDDHRRNLGHTTASGAIKDQISGYEGGAKSAQPAWDAY
MKAVLEGVPEQPLTPPPGIVTVNIDRSTGQLANGGNSREEYFIEGTQPTQQAVHEVGTTI
IDNGEAQELF

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits)

# Drug_Target_6_SwissProt_ID:
P02918

# Drug_Target_6_SwissProt_Name:
PBPA_ECOLI

# Drug_Target_6_Synonyms:
DD-transpeptidase
EC 2.4.2.-
EC 3.4.-.-
PBP-1a
PBP1a
Penicillin-sensitive transpeptidase
Peptidoglycan TGase

# Drug_Target_6_Theoretical_pI:
6.53

# Drug_Target_6_Transmembrane_Regions:
6-26

# Drug_Target_7_Cellular_Location:
Bacterial cell inner membrane
single-pass type II membrane protein

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
10223931	Kohler J, Dorso KL, Young K, Hammond GG, Rosen H, Kropp H, Silver LL: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother. 1999 May;43(5):1170-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
X02163

# Drug_Target_7_GenBank_ID_Protein:
42468

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
mrcB

# Drug_Target_7_Gene_Sequence:
>2535 bp
ATGGCCGGGAATGACCGCGAGCCAATTGGACGCAAAGGGAAACCGACGCGTCCGGTCAAA
CAAAAGGTAAGCCGTCGTCGTTACGAAGATGACGATGATTACGACGATTATGATGACTAT
GAGGATGAAGAACCGATGCCGCGCAAAGGTAAGGGCAAAGGCAAAGGGCGTAAGCCTCGT
GGCAAACGCGGCTGGCTATGGCTACTGCTAAAACTGGCTATCGTTTTTGCCGTGCTGATC
GCCATTTACGGCGTTTATCTCGATCAAAAAATTCGTAGCCGTATTGATGGCAAGGTCTGG
CAACTCGCTGCGGCAGTTTATGGCCGAATGGTCAATCTTGAGCCAGACATGACCATCAGC
AAGAACGAGATGGTGAAGCTGCTGGAGGCGACCCAGTATCGTCAGGTGTCGAAAATGACC
CGTCCTGGCGAATTTACCGTGCAGGCCAACAGCATTGAGATGATTCGCCGTCCGTTTGAT
TTCCCGGACAGTAAAGAAGGACAGGTGCGCGCGCGTCTGACCTTTGATGGCGATCATCTG
GCGACGATCGTCAATATGGAGAACAACCGTCAGTTCGGTTTCTTCCGTCTTGATCCGCGT
CTGATCACCATGATCTCTTCGCCAAACGGTGAGCAGCGTCTGTTTGTGCCGCGCAGTGGT
TTCCCGGATTTGCTGGTGGATACTTTGCTGGCGACAGAAGACCGTCATTTTTACGAGCAT
GATGGAATCAGTCTCTACTCAATCGGACGTGCGGTGCTGGCAAACCTGACCGCCGGACGC
ACGGTACAGGGTGCGAGTACGCTGACGCAACAGCTGGTGAAAAACCTGTTCCTCTCCAGC
GAGCGTTCTTACTGGCGTAAAGCGAACGAAGCTTACATGGCGCTGATCATGGACGCGCGT
TACAGCAAAGACCGTATTCTTGAGCTGTATATGAACGAGGTGTATCTCGGTCAGAGCGGC
GACAACGAAATCCGCGGCTTCCCGCTGGCAAGCTTGTATTACTTTGGTCGCCCGGTAGAA
GAGCTAAGCCTCGACCAGCAGGCGCTGTTAGTCGGTATGGTGAAAGGGGCGTCCATCTAC
AACCCGTGGCGTAACCCAAAACTGGCGCTGGAGCGACGTAATCTGGTGCTGCGTCTGCTG
CAACAGCAACAGATTATTGATCAAGAACTCTATGACATGTTGAGTGCCCGTCCGCTGGGG
GTTCAGCCGCGCGGTGGGGTGATCTCTCCTCAGCCAGCCTTTATGCAACTGGTGCGTCAG
GAGCTGCAGGCAAAACTGGGCGATAAGGTAAAAGATCTCTCCGGCGTGAAGATCTTCACT
ACCTTTGACTCGGTGGCCCAGGACGCGGCAGAAAAAGCCGCCGTGGAAGGCATTCCGGCA
CTGAAGAAACAGCGTAAGTTGAGCGATCTTGAAACTGCGATTGTGGTCGTCGACCGCTTT
AGTGGTGAAGTTCGTGCGATGGTCGGAGGTTCTGAGCCGCAGTTTGCGGGCTACAACCGT
GCGATGCAGGCGCGTCGTTCGATTGGTTCCCTTGCAAAACCAGCGACTTATCTGACGGCC
TTAAGCCAGCCGAAAATCTATCGTCTGAATACGTGGATTGCGGATGCGCCAATTGCGCTG
CGTCAGCCGAATGGCCAGGTCTGGTCACCGCAGAATGATGACCGTCGTTATAGCGAAAGC
GGCAGAGTGATGCTGGTGGATGCGTTGACCCGTTCGATGAACGTGCCGACGGTAAATCTG
GGGATGGCGCTGGGGCTGCCTGCGGTTACGGAGACCTGGATTAAACTGGGCGTACCGAAA
GATCAGTTGCATCCGGTTCCGGCAATGCTGCTGGGGGCGTTGAACTTAACGCCAATCGAA
GTGGCGCAGGCATTCCAGACCATCGCCAGCGGTGGTAACCGTGCACCGCTTTCTGCGCTG
CGTTCGGTAATCGCGGAAGATGGCAAAGTGCTGTATCAGAGCTTCCCGCAGGCGGAACGC
GCTGTTCCGGCGCAGGCGGCGTATCTGACACTATGGACCATGCAGCAGGTGGTACAACGC
GGTACGGGTCGTCAGCTTGGGGCGAAATACCCGAACCTGCATCTGGCAGGGAAAACAGGG
ACTACCAACAATAACGTAGATACCTGGTTTGCGGGCATTGACGGCAGCACGGTGACCATC
ACCTGGGTCGGCCGTGATAACAACCAGCCGACCAAACTGTATGGTGCCAGCGGGGCAATG
TCGATTTATCAGCGTTATCTGGCTAACCAGACGCCAACGCCGCTGAATCTTGTTCCGCCA
GAAGATATTGCAGATATGGGCGTGGACTACGACGGCAACTTTGTTTGCAGCGGTGGCATG
CGTATCTTGCCGGTCTGGACCAGCGATCCGCAATCGCTGTGCCAGCAGAGCGAGATGCAG
CAGCAGCCGTCAGGCAATCCGTTTGATCAGTCTTCTCAGCCGCAGCAACAGCCGCAACAG
CAACCTGCTCAGCAAGAGCAGAAAGACAGCGACGGTGTAGCCGGTTGGATCAAGGATATG
TTTGGTAGTAATTAA

# Drug_Target_7_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_7_General_References:
10037771	Vollmer W, von Rechenberg M, Holtje JV: Demonstration of molecular interactions between the murein polymerase PBP1B, the lytic transglycosylase MltA, and the scaffolding protein MipA of Escherichia coli. J Biol Chem. 1999 Mar 5;274(10):6726-34.
10564478	Terrak M, Ghosh TK, van Heijenoort J, Van Beeumen J, Lampilas M, Aszodi J, Ayala JA, Ghuysen JM, Nguyen-Disteche M: The catalytic, glycosyl transferase and acyl transferase modules of the cell wall peptidoglycan-polymerizing penicillin-binding protein 1b of Escherichia coli. Mol Microbiol. 1999 Oct;34(2):350-64.
1885547	Zijderveld CA, Aarsman ME, den Blaauwen T, Nanninga N: Penicillin-binding protein 1B of Escherichia coli exists in dimeric forms. J Bacteriol. 1991 Sep;173(18):5740-6.
3330753	Edelman A, Bowler L, Broome-Smith JK, Spratt BG: Use of a beta-lactamase fusion vector to investigate the organization of penicillin-binding protein 1B in the cytoplasmic membrane of Escherichia coli. Mol Microbiol. 1987 Jul;1(1):101-6.
3882429	Broome-Smith JK, Edelman A, Yousif S, Spratt BG: The nucleotide sequences of the ponA and ponB genes encoding penicillin-binding protein 1A and 1B of Escherichia coli K12. Eur J Biochem. 1985 Mar 1;147(2):437-46.
3920658	Keck W, Glauner B, Schwarz U, Broome-Smith JK, Spratt BG: Sequences of the active-site peptides of three of the high-Mr penicillin-binding proteins of Escherichia coli K-12. Proc Natl Acad Sci U S A. 1985 Apr;82(7):1999-2003.
8202364	Fujita N, Mori H, Yura T, Ishihama A: Systematic sequencing of the Escherichia coli genome: analysis of the 2.4-4.1 min (110,917-193,643 bp) region. Nucleic Acids Res. 1994 May 11;22(9):1637-9.
8645198	Wang CC, Schultz DE, Nicholas RA: Localization of a putative second membrane association site in penicillin-binding protein 1B of Escherichia coli. Biochem J. 1996 May 15;316 ( Pt 1):149-56.
9244263	Lefevre F, Remy MH, Masson JM: Topographical and functional investigation of Escherichia coli penicillin-binding protein 1b by alanine stretch scanning mutagenesis. J Bacteriol. 1997 Aug;179(15):4761-7.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9841666	Goffin C, Ghuysen JM: Multimodular penicillin-binding proteins: an enigmatic family of orthologs and paralogs. Microbiol Mol Biol Rev. 1998 Dec;62(4):1079-93.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
543

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
94294

# Drug_Target_7_Name:
Penicillin-binding protein 1B

# Drug_Target_7_Number_of_Residues:
844

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00905	Transpeptidase
PF00912	Transgly

# Drug_Target_7_Protein_Sequence:
>Penicillin-binding protein 1B
MAGNDREPIGRKGKPTRPVKQKVSRRRYEDDDDYDDYDDYEDEEPMPRKGKGKGKGRKPR
GKRGWLWLLLKLAIVFAVLIAIYGVYLDQKIRSRIDGKVWQLPAAVYGRMVNLEPDMTIS
KNEMVKLLEATQYRQVSKMTRPGEFTVQANSIEMIRRPFDFPDSKEGQVRARLTFDGDHL
ATIVNMENNRQFGFFRLDPRLITMISSPNGEQRLFVPRSGFPDLLVDTLLATEDRHFYEH
DGISLYSIGRAVLANLTAGRTVQGASTLTQQLVKNLFLSSERSYWRKANEAYMALIMDAR
YSKDRILELYMNEVYLGQSGDNEIRGFPLASLYYFGRPVEELSLDQQALLVGMVKGASIY
NPWRNPKLALERRNLVLRLLQQQQIIDQELYDMLSARPLGVQPRGGVISPQPAFMQLVRQ
ELQAKLGDKVKDLSGVKIFTTFDSVAQDAAEKAAVEGIPALKKQRKLSDLETAIVVVDRF
SGEVRAMVGGSEPQFAGYNRAMQARRSIGSLAKPATYLTALSQPKIYRLNTWIADAPIAL
RQPNGQVWSPQNDDRRYSESGRVMLVDALTRSMNVPTVNLGMALGLPAVTETWIKLGVPK
DQLHPVPAMLLGALNLTPIEVAQAFQTIASGGNRAPLSALRSVIAEDGKVLYQSFPQAER
AVPAQAAYLTLWTMQQVVQRGTGRQLGAKYPNLHLAGKTGTTNNNVDTWFAGIDGSTVTI
TWVGRDNNQPTKLYGASGAMSIYQRYLANQTPTPLNLVPPEDIADMGVDYDGNFVCSGGM
RILPVWTSDPQSLCQQSEMQQQPSGNPFDQSSQPQQQPQQQPAQQEQKDSDGVAGWIKDM
FGSN

# Drug_Target_7_Reaction:
[GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)]n- diphosphoundecaprenol + GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)- diphosphoundecaprenol = [GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)]n+1- diphosphoundecaprenol + undecaprenyl diphosphate

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan strands) and a penicillin-sensitive transpeptidase C-terminal domain (cross-linking of the peptide subunits)

# Drug_Target_7_SwissProt_ID:
P02919

# Drug_Target_7_SwissProt_Name:
PBPB_ECOLI

# Drug_Target_7_Synonyms:
EC 2.4.1.129
EC 3.4.-.-
Murein polymerase
PBP-1b
PBP1b
Penicillin- sensitive transpeptidase
Peptidoglycan TGase
Peptidoglycan glycosyltransferase

# Drug_Target_7_Theoretical_pI:
9.46

# Drug_Target_7_Transmembrane_Regions:
64-87

# Drug_Target_8_Cellular_Location:
Cell inner membrane

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
10223931	Kohler J, Dorso KL, Young K, Hammond GG, Rosen H, Kropp H, Silver LL: In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother. 1999 May;43(5):1170-6.

# Drug_Target_8_Essentiality:
Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
X06480

# Drug_Target_8_GenBank_ID_Protein:
41218

# Drug_Target_8_GeneCard_ID:
dacC

# Drug_Target_8_Gene_Name:
dacC

# Drug_Target_8_Gene_Sequence:
>1203 bp
ATGACGCAATACTCCTCTCTCCTTCGTGGTCTTGCAGCGGGTTCTGCATTTTTATTCCTT
TTTGCCCCAACGGCATTCGCGGCGGAACAAACCGTTGAAGCGCCGAGCGTGGATGCGCGT
GCATGGATTTTAATGGATTACGCCAGCGGTAAAGTGCTGGCAGAAGGCAATGCGGATGAG
AAACTGGATCCCGCGAGCCTGACTAAAATCATGACCAGCTATGTGGTTGGGCAGGCGCTT
AAGGCCGATAAGATTAAACTCACCGATATGGTGACCGTCGGTAAAGATGCCTGGGCGACG
GGAAATCCGGCACTGCGTGGTTCATCGGTAATGTTCCTCAAACCGGGCGATCAGGTTTCG
GTGGCAGACTTGAACAAAGGTGTGATTATCCAGTCCGGTAATGACGCCTGTATTGCGCTG
GCTGATTACGTTGCCGGGAGCCAGGAGTCATTTATTGGTCTGATGAATGGTTATGCCAAA
AAACTGGGTCTGACCAACACTACCTTCCAGACGGTGCACGGCCTGGATGCGCCGGGGCAG
TTCAGCACCGCGCGCGATATGGCATTGCTGGGTAAAGCATTGATCCACGATGTGCCGGAA
GAGTACGCCATTCATAAAGAGAAAGAGTTCACCTTCAACAAAATTCGTCAGCCTAACCGT
AACCGTCTGCTGTGGAGCAGCAATCTGAATGAAGATGGCATGAAGACAGGAACCACGGCA
GGCGCGGGATATAATCTGGTTGCTTCGGCTACCCAGGGCGATATGCGTTTAATCTCCGTA
GTGTTGGGGGCGAAAACCGACCGTATCCGTTTTAATGAGTCTGAGAAATTATTGACCTGG
GGTTTCCGCTTCTTTGAAACCGTGACGCCAATTAAACCTGATGCCACCTTTGTGACTCAG
CGCGTCTGGTTTGGTGATAAGAGCGAAGTGAATCTCGGGGCAGGTGAAGCGGGCTCAGTG
ACCATACCGCGTGGGCAGCTGAAAAACCTGAAAGCGAGTTATACGTTAACGGAACCGCAG
CTTACCGCACCGCTGAAAAAAGGTCAGGTTGTCGGGACCATTGATTTCCAGCTTAACGGT
AAATCCATTGAGCAGCGTCCGCTGATCGTGATGGAAAATGTGGAAGAGGGCGGATTCTTT
GGTCGGGTGTGGGATTTCGTGATGATGAAATTCCATCAGTGGTTCGGCAGCTGGTTCTCT
TAA

# Drug_Target_8_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_8_General_References:
16738553	Hayashi K, Morooka N, Yamamoto Y, Fujita K, Isono K, Choi S, Ohtsubo E, Baba T, Wanner BL, Mori H, Horiuchi T: Highly accurate genome sequences of Escherichia coli K-12 strains MG1655 and W3110. Mol Syst Biol. 2006;2:2006.0007. Epub 2006 Feb 21.
3279397	Broome-Smith JK, Ioannidis I, Edelman A, Spratt BG: Nucleotide sequences of the penicillin-binding protein 5 and 6 genes of Escherichia coli. Nucleic Acids Res. 1988 Feb 25;16(4):1617.
7042389	Waxman DJ, Amanuma H, Strominger JL: Amino acid sequence homologies between Escherichia coli penicillin-binding protein 5 and class A beta-lactamases. FEBS Lett. 1982 Mar 22;139(2):159-63.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-62.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
6184

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
43608.6

# Drug_Target_8_Name:
D-alanyl-D-alanine carboxypeptidase dacC

# Drug_Target_8_Number_of_Residues:
400

# Drug_Target_8_PDB_ID:
Not Available

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00768	Peptidase_S11
PF07943	PBP5_C

# Drug_Target_8_Protein_Sequence:
>D-alanyl-D-alanine carboxypeptidase dacC
MTQYSSLLRGLAAGSAFLFLFAPTAFAAEQTVEAPSVDARAWILMDYASGKVLAEGNADE
KLDPASLTKIMTSYVVGQALKADKIKLTDMVTVGKDAWATGNPALRGSSVMFLKPGDQVS
VADLNKGVIIQSGNDACIALADYVAGSQESFIGLMNGYAKKLGLTNTTFQTVHGLDAPGQ
FSTARDMALLGKALIHDVPEEYAIHKEKEFTFNKIRQPNRNRLLWSSNLNVDGMKTGTTA
GAGYNLVASATQGDMRLISVVLGAKTDRIRFNESEKLLTWGFRFFETVTPIKPDATFVTQ
RVWFGDKSEVNLGAGEAGSVTIPRGQLKNLKASYTLTEPQLTAPLKKGQVVGTIDFQLNG
KSIEQRPLIVMENVEEGGFFGRVWDFVMMKFHQWFGSWFS

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
1-27

# Drug_Target_8_Specific_Function:
Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors

# Drug_Target_8_SwissProt_ID:
P08506

# Drug_Target_8_SwissProt_Name:
DACC_ECOLI

# Drug_Target_8_Synonyms:
DD-carboxypeptidase
DD-peptidase
PBP-6
Penicillin-binding protein 6

# Drug_Target_8_Theoretical_pI:
8.38

# Drug_Target_8_Transmembrane_Regions:
None

#END_DRUGCARD DB00303
